How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,722 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. (PubMed)

Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. Mycosis fungoides (MF) and parapsoriasis are characterized by malignant proliferation and chronic inflammation, which may affect the risk for venous thromboembolism (VTE).To examine the risk for VTE in patients with MF and parapsoriasis.We conducted a nationwide population-based cohort study in Denmark to examine the relative risk (RR) of VTE in 525 patients

2017 Journal of American Academy of Dermatology

102. Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and sezary syndrome. (PubMed)

Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and sezary syndrome. While mycosis fungoides (MF) is typically an indolent malignancy, it may infrequently undertake an aggressive course. We used proteomic analyses to identify a biomarker of the aggressive course of MF. Results of this investigation demonstrated that PARP-1, heat-shock protein family A (Hsp70) member 1 like (HSAP1L), Hsp70 member 1A (HSPA1A), ATP-depending RNA helicase (DDX17) and the α-isoform

2017 Experimental Dermatology

103. Standardization of regimens in Narrow-band UVB and PUVA in early stage Mycosis Fungoides: position paper from the Italian Task Force for Cutaneous Lymphomas. (PubMed)

Standardization of regimens in Narrow-band UVB and PUVA in early stage Mycosis Fungoides: position paper from the Italian Task Force for Cutaneous Lymphomas. UV-based (PUVA and narrowband UVB) phototherapy is broadly and commonly used in the treatment of Cutaneous T-cell Lymphomas (CTCL), yet unfortunately, the evidence for the efficacy of these treatments is based only on case series or prospective but non-randomized studies. Therefore, no internationally approved guidelines exist

2017 Journal of the European Academy of Dermatology and Venereology

104. The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. (PubMed)

The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. Total skin electron beam radiation therapy (TSEB) is a very effective treatment of mycosis fungoides. Following reports of similar durations of response to lower doses of TSEB, a low-dose schedule of TSEB was introduced in the United Kingdom.A protocol of 12 Gy in 8 fractions over a period of 2 weeks was agreed on by use of the Stanford University (...) with stage IB disease compared with 11.3 months in patients with stage IIB (P=.003; hazard ratio, 2.66) and 10.2 months in patients with stage III (P=.002; hazard ratio, 4.62). The treatment was well tolerated with lower toxicity than higher-dose schedules.The low-dose TSEB schedule of 12 Gy in 8 fractions over a period of 2 weeks is well tolerated and is an effective option for patients with mycosis fungoides.Copyright © 2017 Elsevier Inc. All rights reserved.

2017 Biology and Physics

105. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series. (PubMed)

Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series. To demonstrate the clinical efficacy of topical 5% imiquimod for mycosis fungoides (MF) tumors.Treatment of tumor-stage MF represents a therapeutic challenge because of a limited number of effective topical therapies. Single tumors can be treated with localized radiation but may recur. Systemic therapies are also an option but are associated with serious adverse effects. Imiquimod is a topical agent whose

2017 Journal of Dermatological Treatment

106. CD8<sup>+</sup> mycosis fungoides: A low-grade lymphoproliferative disorder. (PubMed)

CD8+ mycosis fungoides: A low-grade lymphoproliferative disorder. The prognosis of the CD8+ subtype of mycosis fungoides (MF) is controversial. Although most authors believe that determining the presence of this cell surface antigen has no prognostic value, others have observed a more indolent course for CD8+ MF compared with CD4+ MF.To review the cases of CD8+ MF in the pediatric and adult populations seen at our institution.This is a retrospective review of clinical and pathologic

2017 Journal of American Academy of Dermatology

107. Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database. (PubMed)

Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database. Studies have shown contradictory results regarding the survival outcomes among white, African American, and Asian patients with mycosis fungoides (MF).To evaluate the survival outcomes among white, African American, and Asian patients with MF and to determine other prognostic factors of the disease.The US National Cancer Database was used to identify patients with histologically confirmed MF

2017 Journal of American Academy of Dermatology

108. The Effect of Phototherapy on Progression to Tumors in Patients with Patch and Plaque Stage of Mycosis Fungoides. (PubMed)

The Effect of Phototherapy on Progression to Tumors in Patients with Patch and Plaque Stage of Mycosis Fungoides. Phototherapy has been a mainstay in the treatment of mycosis fungoides (MF). However, the recent findings of UV-induced p53 mutations in advanced MF suggest that phototherapy may contribute to disease progression.The objective of this study was to evaluate the effect of phototherapy on the time to tumor progression and overall survival in MF.Retrospective analysis of patients seen

Full Text available with Trip Pro

2017 Journal of Dermatological Treatment

109. Multiple skin cancers in patients with mycosis fungoides after long-term ultraviolet phototherapy. (PubMed)

Multiple skin cancers in patients with mycosis fungoides after long-term ultraviolet phototherapy. Phototherapy is a useful noninvasive therapy, but it can induce cutaneous malignant tumours, including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). We report on a 79-year-old man who had long-standing mycosis fungoides for 40 years, which had been treated with psoralen ultraviolet A therapy for 37 years at a dose of approximately 5000 J/cm2 . Approximately 6 years before

2017 Clinical & Experimental Dermatology

110. Computed Tomography scanning in mycosis fungoides - optimising the balance between benefit and harm. (PubMed)

Computed Tomography scanning in mycosis fungoides - optimising the balance between benefit and harm. 28498608 2018 12 20 1365-2133 178 2 2018 02 The British journal of dermatology Br. J. Dermatol. Computed tomography scanning in mycosis fungoides: optimizing the balance between benefit and harm. 563-564 10.1111/bjd.15657 Spencer A A 0000-0003-3386-8458 Department of Dermatology, University Hospitals Birmingham, Mindelsohn Way, Edgbaston, Birmingham B15 2GW, U.K. Gazzani P P Department

2017 British Journal of Dermatology

111. Folliculotropic Mycosis Fungoides with Skewed T-cell Receptor CDR3 motif: Suggestive of Lipid Antigen-selection? (PubMed)

Folliculotropic Mycosis Fungoides with Skewed T-cell Receptor CDR3 motif: Suggestive of Lipid Antigen-selection? Folliculotropic mycosis fungoides (FMF), a variant of mycosis fungoides (MF) with distinct clinical features, is characterized by infiltration of malignant T cells in hair follicles. This raises the hypothesis that antigens in the hair follicle may contribute to the pathogenesis of FMF. T-cell receptor β gene (TRB) sequences as well as dendritic cell subsets in patients with FMF (n

Full Text available with Trip Pro

2017 Acta Dermato-Venereologica

112. Tumor-stage mycosis fungoides regressing with milia and pustules after total skin electron beam therapy. (PubMed)

Tumor-stage mycosis fungoides regressing with milia and pustules after total skin electron beam therapy. 28557155 2017 10 23 1468-3083 31 10 2017 Oct Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Tumour-stage mycosis fungoides regressing with milia and pustules after total skin electron beam therapy. e440 10.1111/jdv.14372 Puiu T T University of Michigan Medical School, Ann Arbor, 48103, MI, USA. Porto D A DA Department of Dermatology, Henry

2017 Journal of the European Academy of Dermatology and Venereology

113. Psoriasis in patients with Mycosis Fungoides: Α clinicopathological study of 25 patients. (PubMed)

Psoriasis in patients with Mycosis Fungoides: Α clinicopathological study of 25 patients. It has been reported that patients with psoriasis are at increased risk for developing lymphoma including cutaneous T-cell lymphomas (CTCL). However, the comorbidity and the histopathologic correlation of psoriasis and mycosis fungoides (MF) have been less studied.The objective of this study was to investigate the relation between MF and psoriasis.We retrospectively reviewed and re-evaluated all MF cases

2017 Journal of the European Academy of Dermatology and Venereology

114. The role of macrophages in the pathogenesis of mycosis fungoides. (PubMed)

The role of macrophages in the pathogenesis of mycosis fungoides. Macrophages are classified into classically activated (M1) and alternatively activated (M2) macrophages. Decrease in macrophage number in tumour tissue with treatment has been reported.The aim of this study was to determine whether treatment has an effect on the number of dermal M1 and M2 macrophages in patients with mycosis fungoides (MF).In total, 21 patients (8 women, 13 men; age range 42-73 years) were included in this study

2017 Clinical & Experimental Dermatology

115. Ultraviolet A1 Phototherapy in the Treatment of Early Mycosis Fungoides. (PubMed)

Ultraviolet A1 Phototherapy in the Treatment of Early Mycosis Fungoides. Phototherapy has been the mainstay of therapies for early mycosis fungoides (MF). The beneficial role of ultraviolet (UV) light on MF is suggested by the observation that lesions occur on non-sun-exposed areas. Therapeutic light sources that are available today are broadband UVB, psoralen and UVA, narrowband UVB, and long-wave UV (UVA1). Current literature provides increasing evidence on the use of UVA1 to treat MF.To

Full Text available with Trip Pro

2017 Dermatology

116. Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. (PubMed)

Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached.To determine whether dose escalation

Full Text available with Trip Pro

2017 JAMA dermatology (Chicago, Ill.)

117. High Expression of Fas/CD95 on CD4+ Circulating T-cells: An Exclusion Criterion in the Diagnosis of Mycosis Fungoides? (PubMed)

High Expression of Fas/CD95 on CD4+ Circulating T-cells: An Exclusion Criterion in the Diagnosis of Mycosis Fungoides? The aim of this 10-year monocentric prospective study was to determine a cut-off value of Fas/CD95 expression by peripheral blood CD4+ T lymphocytes in discriminating patients with mycosis fungoides from controls with cutaneous benign lymphocytic conditions. CD95 expression in peripheral blood CD4+ T lymphocytes was measured using flow cytometry in 330 patients referred (...) for diagnosis: 104 with mycosis fungoides and 226 with eczema, psoriasis, drug reaction, etc. The sensitivity and specificity of different thresholds of CD95 expression were calculated regarding the final diagnosis of patients with mycosis fungoides or controls. CD95 expression higher than 30% reached a specificity of 91% in ruling out a diagnosis of mycosis fungoides, although overall CD95 expression was not significantly different from that of controls (p = 0.309) and sensitivity was very low (5%). Thus

Full Text available with Trip Pro

2017 Acta Dermato-Venereologica

120. Expression of Mucin 1 in Mycosis Fungoides Tumour Cells: A Case Report. (PubMed)

Expression of Mucin 1 in Mycosis Fungoides Tumour Cells: A Case Report. 28218332 2018 03 16 2018 03 16 1651-2057 97 6 2017 06 09 Acta dermato-venereologica Acta Derm. Venereol. Expression of Mucin 1 in Mycosis Fungoides Tumour Cells: A Case Report. 747-748 10.2340/00015555-2638 Shirai Takushi T Department of Dermatology, Shinshu University School of Medicine,, 3908621 Matsumoto, Japan. Kiniwa Yukiko Y Asaka Shiho S Shimojo Yasuyo Y Kamijo Fuminao F Okuyama Ryuhei R eng Case Reports Journal (...) Article Sweden Acta Derm Venereol 0370310 0001-5555 0 MUC1 protein, human 0 Mucin-1 IM Female Humans Immunohistochemistry Middle Aged Mucin-1 analysis Mycosis Fungoides chemistry Skin Neoplasms chemistry 2017 2 22 6 0 2018 3 17 6 0 2017 2 21 6 0 ppublish 28218332 10.2340/00015555-2638

Full Text available with Trip Pro

2017 Acta Dermato-Venereologica

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>